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Abstract 
Background. Recent evidence suggests that erythromycin (EM), a major macrolide 
antibiotic, has many biological functions in addition to the anti-bacterial actions, 
including anti-inflammatory and free radical scavenging actions. However, the effects 
of the drug upon inflammatory myocardial diseases are unknown. We tested the 
hypothesis that EM ameliorates experimental autoimmune myocarditis in rats 
attributing to the suppression of superoxide production. Methods. We administered 
EM, 3.3mg/kg/day and 33mg/kg/day, intraperitoneally for 3 weeks, to rats with 
experimental autoimmune myocarditis (EAM) produced by immunization by porcine 
myosin. Results. EM treatment reduced the severity of myocarditis compared with the 
untreated group in a dose-dependent manner by comparing the heart weight/body 





infiltrations. Echocardiographic study showed that increased left ventricular posterior 
wall thickness produced by myocardial inflammation was reduced by EM treatment. 
Myocardial superoxide production, determined by dihydroethidium staining, was 
significantly reduced by the treatment. Western blotting showed that the expression of 
myocardial interleukin-1 was reduced by EM treatment compared with untreated 
groups. The in vivo dorsal air pouch model showed that EM significantly suppressed 
leukocyte chemotaxis in a dose-dependent manner. Conclusion. Irrespective of a 
well-known classic antibiotic, EM attenuated EAM not only by the anti-inflammatory 
action but by the suppression of superoxide production.  
 
Keywords: autoimmune myocarditis; erythromycin; 14- member ring macrolides;  
          superoxide production 
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1. Introduction 
 In humans, acute myocarditis is a potentially lethal disease, and frequently 
precedes the development of dilated cardiomyopathy (DCM). In general, two major 
mechanisms to explain how myocarditis develops into DCM have been proposed; one is 
a persistent antigen existence, and the other is a progressive autoimmune myocardial 
injury 
(1)
. The autoimmune giant cell myocarditis in rats, i.e., experimental autoimmune 
myocarditis (EAM), mimics human fulminant myocarditis in the acute phase
 (2)
. 
 Erythromycin (EM) is known as a classic 14-member ring macrolide and a potent 
antibiotic for the treatment of various microbial infections
 (3)
. Recently, macrolides, 
including EM, have been reported to have multiple biologic effects, such as alteration of 
inflammatory and free radical actions
 (4-6)
. It was demonstrated that free radicals play an 
important role in the development of heart failure in this animal model 
(7)
. However, the 
effects of EM upon inflammatory myocardial diseases are still unknown. 
 The purpose of the present study was to examine the effects of EM upon an EAM 
model, focusing on its inhibitory effects on the production of inflammatory cytokines 
and free radicals. 
2. Materials and Methods 
2.1. Immunization  
 EAM was induced in Lewis rats by immunization with porcine cardiac myosin as 
previously described 
(8-10)
. Porcine cardiac myosin (Sigma) was injected subcutaneously 
in the foot pads with 0.1 ml of myosin (10 mg/ml) mixed with an equal volume of 
Freund's complete adjuvant (FCA) supplemented with Mycobacterium tuberculosis 
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H37Ra (Difco) on days 1 and 8. Control rats were immunized with FCA alone. The 
animals were daily observed up to the end of the experiment on day 21. The day of 
injection was designated day 1.  
 Rats surviving 21 days after myosin or FCA immunization were used for the 
cardiac function study, and thereafter were sacrificed. 
2.2 Medication 
 Rats with EAM were divided into three groups and treated intraperitoneally with 
phosphate buffered saline (PBS) (untreated group, n=15) and EM (3.3mg/kg/day, n=15 
and 33mg/kg/day, n=10) for three weeks (immunized protocol). These doses were 
chosen because of the previous studies 
(4-6)
. In parallel with the protocol, additional 
control groups (unimmunized protocol) were age-matched unimmunized rats treated for 
21 days with PBS (untreated group, n=5) and EM (3.3mg/kg/day, n=5 and 33mg/kg/day, 
n=5). All the mice were sacrificed three weeks thereafter. Organ weights were 
determined. Organs including the skins at dorsal air pouch were processed for the 
pathologic study. The animals were sacrificed under the light ether anesthesia at the end 
of experiments. 
 We performed animal experiments in accordance with the Guide for the Care and 
Use of Laboratory Animals published by the US National Institutes of Health (NIH 
Publication No.85-23, revised 1996), and these were approved by the institutional ethics 
committee for animal experiments of Kyoto University. 
2.3. Histopathology 
 At sacrifice, macroscopic findings were performed. Microscopic findings for 
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myocardial necrosis and cellular infiltration were graded on a scale of 0 to +5, as 
previously described
 (8-10)
. That is, myocardial sections were graded by two of the 
authors (K.S., C.K.) who had no knowledge of the respective treatment groups on a 
scale of 1+ (mild) to 5+ (very severe) for the severity
 (8-10)
. After macroscopic 
examination, a part of the ventricles was embedded in OCT for immunohistochemistry. 
2.4. Immunohistochemical staining 
 We used an immunoperoxidase technique to perform immunohistochemistry for 
cell surface markers, as previously described
 (8-10)
. In brief, anti-macrophage (anti-M, 
ED1, 1:400, PharMingen), anti-CD4 (GK1.5, 1:50, PharMingen), and anti-CD8 (53-6.7, 
1:50, PharMingen) antibodies were applied to acetone-fixed cryosections. After being 
washed, the sections were then exposed to a second antibody (horseradish 
peroxidase-conjugated antibodies), and the antibody was visualized with 
diaminobenzidine. Sections were counterstained with 1% methyl green. The 
positive-staining cells of heart tissue were counted blindly by two observers in six fields 
at  400 magnification (within a 1-mm2 grid), and the total positive-staining cells of the 
six fields were recorded as the number of infiltrating cells in the lesions. The percentage 
of stained cell was then calculated for each antibody staining section 
(8,11)
.  
2.5. In situ detection of superoxide production in hearts 
 To evaluate in situ superoxide production from hearts, unfixed frozen cross 
sections of the specimens were stained with dihydroethidium (DHE; Molecular Probe, 
OR) according to the previously validated method 
(11-14)
. In the presence of superoxide, 
DHE is converted to the fluorescent molecule ethidium, which can then label nuclei by 
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intercalating with DNA. Briefly, the unfixed frozen tissues were cut into 10-m thick 
sections, and incubated with 10 M DHE at 37 C for 30 min in a light-protected 
humidified chamber. The images were obtained with a laser scanning confocal 
microscope. Superoxide production was demonstrated by red fluorescence labeling. 
 For quantification of ethidium fluorescence from hearts, fluorescence (intensity x 
area) was measured in five randomly selected fields using the high-power image 
monitor. 
2.6. Western blotting 
 Western blot analysis for interleukin-1 (IL-1) was performed as described 
previously 
(7,9,10)
. The myocardial lysates were electrophoresed using sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were sequentially 
electrophoretically transferred to a membrane (Millipore). The membrane was 
incubated with an anti-IL-1 antibody (Serotec) and then with a peroxidase-linked 
secondary antibody (Amersham). The glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) samples were probed in the blots as internal controls for loading. Resulting 
bands were quantified as optical density band area by the image analysis system. 
2.7. Echocardiographic and hemodynamic studies 
 Echocardiography was performed on day 21 post-myosin injection for the 
subpopulation of control (immunized and unimmunized) and EM (33mg/kg/day, 
immunized and unimmunized) groups. Rats were anesthetized with an intraperitoneal 
injection of 0.040 to 0.060 mg/mg sodium pentobarbital. A 12 MHz probe was placed at 
the left 4th intercostal space for M-mode imaging using 2D echocardiography (Sonos 
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5500, Philips). Left ventricular (LV) end-diastolic dimension (LVDd), left ventricular 
end-systolic dimension (LVDs), interventricular septum (IVS) thickness, and posterior 
wall (PW) thickness were measured, as an average of three beats. Ejection fraction (EF) 




2.8. Chemotaxis in vivo 
 A dorsal air pouch was created as previously described
(15)
. Briefly, rats were 
injected on the back subcutaneously with 4 ml of air under the anesthesia of sodium 
pentobarbital on day 10. PBS (0.3ml) was injected into the air pouch. Air pouch was 
maintained up to day 20. The air pouch was flushed quantitatively with PBS, and four 
hours later, the volume recovered was measured. The number of cells was determined 
with a hemocytometer. The exudating cell numbers into the air pouch on day 20 were 
calculated. The cutaneous tissues at the dorsal air pouch were pathologically examined. 
2.9. Statistical analysis 
 All values were expressed as meansstandard deviation (SD). One way analysis 
of variance (ANOVA), following by Fisher protected least significant difference test, 
was performed. A value of P<0.05 was considered statistically significant. 
3. Results 
3.1. General clinical findings 
 No rats died in all groups during three weeks of the study.  
3.2. Histopathology and organ weights in rats with acute EAM (Tables 1, 2) 
 Extensive injuries to myocytes with inflammatory changes and multinucleated 
giant cells associated with ED1 (macrophage) expression were observed (Figure 1). 
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Treatment with EM 33mg/kg/day, but not with EM 3.3mg/kg/day, reduced the severity 
of the disease (Figure 1), as assessed by measuring heart weight/body weight (HW/BW) 
and microscopic scores.  







recruited into the lesions were significantly reduced by the treatment of EM (Figure 1). 
No positive cells were found in the unimmunized groups. 
The dorsal subcutaneous tissue was swollen by the production of air pouch 
compared with the normal tissue. However, the treatment of EM clearly suppressed the 
thickness of the subcutaneous tissue swelling compared with that of untreated mice 
(Figure 2). 
3.3. In situ superoxide production (Table 2) 
 Ethidium fluorescence was detected from the myocardial lesions, and EM 
treatment significantly reduced the intensity of the staining (Figure 1). That is, by the 
treatment of EM, superoxide production was significantly decreased compared with the 
control. 
3.4. Effects of EM on IL-1 expression  
 As shown in Figure 3, inhibitory effect of EM against the expression of 
myocardial IL-1 was demonstrated by the Western blotting. 
3.5. Cardiac function (Table 3, Figure 4) 
 After 3 weeks post-myosin injection, EF tended to slightly decrease in rats with 
myocarditis compared with those of control rats. EM administration did not change 
cardiac function significantly; i.e., the treatment did not produce an increase in EF or a 
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decrease in LVDd compared with the untreated group. Namely, the significant 
improvement of cardiac function compared with the untreated rats was not observed in 
the rats treated with EM. However, EM treatment suppressed the increase of LVPW 
thickness compared with the untreated groups. The increased LVPW at this stage is 
considered to be due to interstitial edema caused by severe myocardial injury.
(10,11)
 
3.6. Effects of EM on chemotaxis (Table 2) 
 The number of leukocytes exudated in the air pouch on day 20 was suppressed by 
EM administration in a dose-dependent manner. 
4. Discussion 
 EM is a classic and potent antibiotic with a 14-member ring macrolide for the 
treatment of various microbial infections, and has multiple biologic effects 
(3-6)
. In this 
report, we have demonstrated for the first time that EM inhibited expression of various 
inflammatory cells in the myocardium and suppressed EAM in rats associated with 
decreased superoxide production. 
 Several studies have described the participation of cytokine overproduction in the 
pathogenesis of heart failure
 (16-18)
. Recent reports indicated that myocardial injury was 
produced by inflammatory cytokines, and that lipid peroxidation was caused by them, 
resulting in cell membrane damage in heart failure
 (19)
. Several studies have definitely 
established the key role of the Th1 cytokine system in the pathogenesis of heart failure 




 In the present study, the immunohistochemical study showed that the numbers of 





T cells were markedly reduced by EM treatment. 
Accordingly, it may be that the main beneficial effects of EM upon EAM may be partly 
due to the suppression of inflammatory events in the myocardium. Indeed it was 
confirmed in the current study that EM administration suppressed the myocardial 
expression of IL-1. The molecular mechanisms of EM for the suppression of 
inflammatory cytokines are not fully understood. However, the inhibition of signal 
transduction pathways, such as NF-B pathway, which is particularly important in the 
regulation of cytokines, has been postulated
 (22-24)
. 
 Next, EM suppressed the generation of free radicals in rats with myocarditis. As a 
result, it may be that EM treatment protected against superoxide-mediated oxidative 
damage in vivo. It was demonstrated that free radicals play an important role in the 
development of heart failure in this animal model 
(7, 11)
. Accordingly, EM treatment may 
act for reducing superoxide production, resulting in less severe myocardial damage in 
rats with myocarditis.  
 Whether EM directly affects the host immune status or not is unknown, it was 
demonstrated, however, in the air pouch study that the numbers of inflammatory cells in 
rats immunized with myosin treated with EM was reduced compared with those 
immunized with myosin and treated with PBS. Furthermore, EM treatment suppressed 
the subcutaneous tissue swelling at air pouch sites, indicating the indirect evidence of 
anti-chemotoxitic activity of the drug. Accordingly, the overall effects of the drug could 
induce the suppression of autoimmune myocarditis associated with the reduction of 
chemotaxis activity.  
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 It was already reported that clarithromycin, another new 14-member ring 
macrolide, has the potential to suppress cardiac rejection by the suppression of matrix 
metalloproteinase in a murine cardiac transplantation model 
(23)
. Recently, it has been 
reported that tetracycline and its derivatives demonstrate the suppressive activity of 
matrix metalloproteinase in a rabbit model of atherosclerosis 
(25)
. In addition, 
tetracyclines also inhibit production of inflammatory cytokines and free radicals, and 
have been used effectively in acute lung injury and chronic inflammatory diseases 
(26, 27)
. 
Most recently, Hishikari et al. 
(28)
 reported the beneficial effects of early treatment of 
clarithromycin upon EAM; they showed that early clarithromycin treatment is effective 
to attenuate myocarditis by suppressing matrix metalloproteinase-9 activity. 
 The lack of the improvement of cardiac function may be due at least in part to the 
characteristic of this model, i.e., the inflammatory process continues until 3 weeks and 
thereafter decreases and then ventricular remodeling begins; the interventricular septal 
and LV posterior wall thickening might be due to the inflammatory changes of the 
myocardium during the acute stage of EAM. As a result, EM exhibited the 
antihypertrophic effect against increased LV mass alone.  
 EM itself is a classic antibiotic agent. From our data, however, EM treatment 
might be promising as a new therapy for heart failure, particularly for ventricular 
remodeling where ongoing autoimmune process may play a role in the disease 
development. In conclusion, EM ameliorates EAM in rats. The cardioprotection of EM 
may be due to the suppression of not only inflammation but superoxide production. 
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Figure Legends 
Figure 1. Pathological findings, DHE stainings, and immunohistological findings 
Severe myocardial necrosis with cellular infiltrates (black arrows) and massive 
superoxide production (white arrows) was seen in the untreated rat with 
myocarditis (upper pannel), but less severe myocardial necrosis with cellular 
infiltrates was noted in the EM (33mg/kg/day) -treated rat with myocarditis 
(lower panel). Serial sections were used in both groups. Arrows in the 
magnified insets (480) indicate giant cells. 
CD4, helper T stain 
CD8, suppressor T stain  
DHE, dihydroethidium 
ED1, macrophage stain 
HE, hematoxylin-eosin 
IH, immunohistology 
 ( 230) 
Figure 2. Cutaneous tissue swelling at air pouch site 
The subcutaneous tissue (B, C, D, E) was swollen by the production of air 
pouch compared with the normal (A). However, the treatment of EM 
(33mg/kg/day) (C, E) clearly suppressed the thickness of the subcutaneous 
tissue swelling compared with that of untreated mice (B, D). 
Hook-shaped width indicates the degree of subcutaneous tissue swelling. 
A; Normal 
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B; myosin-unimmunized, untreated 
C; myosin-unimmunized, EM-treated 
D; myosin-immunized, untreated 
E; myosin-immunized, EM-treated 
HE ( 230) 
Figure 3. Myocardial IL-1 expression 
(A) Representative Western blot analysis showed the decreased expression of 
IL-1in EM (33mg/kg/day)-treated rats with myocarditis compared with 
untreated rats with myocarditis. (B) Densitometric analysis of relative protein 
levels showed that IL-1 expression was increased in rats with myocarditis, 
but was decreased by EM treatment. Values were derived from 5 animals and 
represent a percentage of controls. Lanes were designated as C, control 
(myosin-unimmunized, untreated) rat; EM, myosin-unimmunized, EM 
(33mg/kg/day)-treated rat; M, myocarditis (myosin-immunized, untreated) 
rat; MEM, myosin-immunized, EM (33mg/kg/day)-treated rat. P0.01 vs 
M, † P0.01 vs C. 
Figure 4. Echocardiographic findings 
The significant improvement of cardiac function compared with the untreated 
rats was not observed in the rats treated with EM (33mg/kg/day). However, 
EM treatment (C) suppressed the increase of LVPW (white hook-shaped width) 
compared with the untreated group (B). 
A; myosin-unimmunized, untreated 
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B; myosin-immunized, untreated 






Table 1. Organ weights and cardiac pathology 
 
   BW HW/BW LuW/BW LiW/BW Cardiac Pathology (0~+5) 
  (n) (g) (10-3) (10-3) (10-3) Infiltration Necrosis 
Immunized Protocol 
Control  15 26120 4.50.4 4.30.3 42.34.0 3.20.5 2.80.7 
Erythromycin  3.3mg/kg/day 15 27017 4.30.5 4.10.5 42.23.8 2.70.9 2.50.9 
 33mg/kg/day 10 25810 3.80.4* 4.10.3 41.62.8 1.80.7* 1.90.4* 
 
Unimmunized Protocol 
Control    5 26030 3.80.2 4.30.3 42.04.0 - - - - - - 
Erythromycin  3.3mg/kg/day  5 25825 3.70.4 4.40.4 43.43.8 - - - - - - 
 33mg/kg/day  5 23821 3.90.2 4.00.3 39.04.2 - - - - - - 
        (meanSD) 
HW/BW ratio was lower in the erythromycin group (33mg/kg/day) compared to the control. Semi-quantitative histological grades for 
infiltration and necrosis were significantly lower in the erythromycin group (33mg/kg/day) compared to the control. BW=body weight, 
HW=heart weight, LuW=lung weight, LiW=liver weight, *P < 0.05 v Control. 
Table 2. Immunohistochemistry, chemotaxis and DHE staining 
 







 ( 105) (units) 
Control 20.64.5 15.05.0 7.53.8 25.53.2 1.000.09 
Erythromycin  3.3mg/kg/day 12.73.6* 7.83.2* 4.42.6 18.33.5* 0.820.05* 
 33mg/kg/day 5.85.8** 4.88.6** 3.83.0* 12.44.5** 0.790.08** 
     (mean  SD) 






positive cells in the erythromycin group (3.3mg/kg/day and 33mg/kg/day) were lower than 
in the untreated (control) mice.  
The number of leukocytes exudated into air pouch in unimmunized groups (control group and erythromycin group) ranged from 
16.53.5 105. 
For leukocyte chemotaxis and ethidium fluorescence assay, each trial was independently performed 4-5 times.  
*P < 0.05, **P<0.01 vs Control.  
 
Table 3. Echocardiographic data 
 
EM treatment suppressed the increase of left ventricular LVPWT compared with the untreated groups. EF=ejection fraction, HR=heart 
rate, IVST=interventricular septum thickness, LVDd=left ventricular end-diastolic dimension, LVPWT=left ventricular posterior wall 
thickness. *P<0.05 vs Control. 
   HR LVDd EF IVST LVPWT 
  (n) (hearts/min) (mm) (%) (mm) (mm) 
Immunized Protocol 
Control   8   40716    6.50.3 83.13.6    2.00.6    2.10.3 
Erythromycin 33mg/kg/day  8   40230    6.30.4 82.14.5    1.90.5    1.60.2* 
        
Unimmunized Protocol  
Control  
33mg/kg/day 
 5   4055    6.20.2 86.610.0    1.90.3    1.40.4 
Erythromycin  5   4467    6.00.2 84.67.6    2.00.5    1.50.4 
        
